AffiADA® Infliximab (Remicade) Pharmacokinetic ELISA

Infliximab (Remicade®) is a chimeric monoclonal antibody against tumour necrosis factor alpha (TNF- α). Infliximab neutralizes the biological activity of TNF- α by binding with high affinity to the soluble (free floating in the blood) and transmembrane (located on the outer membranes of T cells and similar immune cells) forms of TNF-α, and inhibits or prevents the effective binding of TNF-α with its receptors.